British Journal of Cancer

Papers
(The H4-Index of British Journal of Cancer is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy623
Cancer health disparities in racial/ethnic minorities in the United States452
Deep learning in cancer pathology: a new generation of clinical biomarkers302
The lingering mysteries of metastatic recurrence in breast cancer268
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond236
Achieving clinical success with BET inhibitors as anti-cancer agents213
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression183
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance162
Insights into the role of sialylation in cancer progression and metastasis137
Tumour treating fields therapy for glioblastoma: current advances and future directions134
How promising is phototherapy for cancer?128
Treatment strategies for breast cancer brain metastases119
Promises and challenges of adoptive T-cell therapies for solid tumours116
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures116
Autophagy as a therapeutic target in pancreatic cancer108
Mutational drivers of cancer cell migration and invasion106
Cysteine metabolic circuitries: druggable targets in cancer106
The untapped potential of ascites in ovarian cancer research and treatment103
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials101
Radiomics and radiogenomics in gliomas: a contemporary update97
The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)86
Endocytosis: a pivotal pathway for regulating metastasis80
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial79
Artificial intelligence in oncology: current applications and future perspectives77
The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 202077
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience77
Metabolic reprogramming in prostate cancer76
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)74
The gut microbiome: what the oncologist ought to know74
Cell-free DNA analysis in current cancer clinical trials: a review74
Cancer immunotherapy: it’s time to better predict patients’ response72
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study70
Radiation-induced bystander and abscopal effects: important lessons from preclinical models70
Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project68
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview68
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma67
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma64
Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer64
Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration64
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials64
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours63
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer63
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours62
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours62
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours61
Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer61
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy61
Biomarkers of response to PD-1 pathway blockade60
Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer60
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects57
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer57
The current treatment landscape in the UK for stage III NSCLC55
Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence55
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations54
Roles of mitochondria in the hallmarks of metastasis54
Long non-coding RNAs are involved in alternative splicing and promote cancer progression54
0.080772876739502